Risk of Lower Selling Prices Due to Healthcare System Reforms and Drug Price Revisions
First written in FY2017. 7 of 11 entries say "Restated". Latest entry: 2026-08-13.
The whole theme swung hardest in 2018: 20 of 65 companies on the "Worse" side.
1 other company's latest entry also says "Mitigated".
- 2026-08-13MitigatedEarnings presentation
「A certain level of gross profit was secured through the improvement in gross margin resulting from supply-price revisions and the switch to products with lower manufacturing costs.」
Against the decline in selling prices and pressure on margins caused by drug-price and cost increases, the effects of supply-price revisions and the switch to lower-cost products were reflected in results. - FY2026WorsenedAnnual report
「Under Japan's drug pricing system, the launch price of a biosimilar is generally set at 70% of the originator product's price, and its price declines in annual revisions under the influence of actual transaction prices at the distribution stage. Meanwhile, manufacturing costs have increased due to inflation in the countries where overseas contractors manufacture the active pharmaceutical ingredients and the depreciation of the yen in foreign exchange markets, affecting the company's profit margin as lower selling prices and higher costs progress simultaneously.」
The company states that the launch price, generally set at 70% of the originator product's price, lower unit prices resulting from annual drug price revisions, and higher costs due to overseas inflation and yen depreciation are simultaneously affecting its profit margin. - FY2025WorsenedAnnual report
「Under Japan's drug pricing system, the launch price of a biosimilar is generally set at 70% of the originator product's price. In addition, as a result of price negotiations with medical institutions and other factors, the price frequently declines in annual drug price revisions.」
Regarding the risk of lower selling prices due to drug price revisions, the company has specifically disclosed that the launch price is generally 70% of the originator product's price and that the price declines through annual revisions and price negotiations. - FY2023-Q3RestatedAnnual report
「During the cumulative third-quarter period, there were no new business risks and no material changes in the business risks described in the annual securities report for the preceding fiscal year.」
The company has disclosed that there have been no material changes in the risk of lower selling prices due to healthcare system reforms and drug price revisions. - FY2020RestatedAnnual report
「Japan has implemented numerous healthcare system reforms, including drug price revisions, to control medical costs, and the company expects this policy to continue in light of the country's aging population.」
The company continues to disclose the risk that healthcare system reforms and drug price revisions may affect active pharmaceutical ingredient selling prices. - FY2019RestatedAnnual report
「Japan has implemented numerous healthcare system reforms, including drug price revisions, to control medical costs, and the company expects this policy to continue in light of the country's aging population.」
The company continues to disclose the risk that healthcare system reforms and drug price revisions may affect active pharmaceutical ingredient selling prices. - FY2019-Q1RestatedAnnual report
「During the cumulative first-quarter period, there were no new business or other risks and no material changes to the business or other risks described in the annual securities report for the previous fiscal year.」
The company has disclosed that there have been no material changes in the risk of lower selling prices due to healthcare system reforms and drug price revisions. - FY2018RestatedAnnual report
「Japan has implemented numerous healthcare system reforms, including drug price revisions, to control medical costs, and the company expects this policy to continue in light of the country's aging population.」
The company continues to disclose the risk that healthcare system reforms and drug price revisions may affect active pharmaceutical ingredient selling prices. - FY2018-Q3RestatedAnnual report
「During the nine months ended September, there were no new business or other risks, nor any material changes to the business or other risks described in the securities report for the prior fiscal year.」
The company has disclosed that there have been no material changes in the risk of lower selling prices due to healthcare system reforms and drug price revisions. - FY2018-Q2RestatedAnnual report
「During the six months ended June, there were no new business or other risks, nor any material changes to the business or other risks described in the securities report for the prior fiscal year.」
The company has disclosed that there have been no material changes in the risk of lower selling prices due to healthcare system reforms and drug price revisions. - FY2017First statedAnnual report
「Japan has implemented numerous healthcare system reforms, including drug price revisions, to control medical costs, and the company expects this policy to continue in light of the country's aging population. Accordingly, the drug price of the company's products under development may be affected when they are launched, which could materially affect the selling prices of the active pharmaceutical ingredients that the company sells to pharmaceutical companies.」
While the spread of generic products is a tailwind, the company has for the first time separately disclosed the risk that policies to control medical costs and drug price revisions may affect active pharmaceutical ingredient selling prices.